靶向GPC3的CAR-T细胞治疗肝癌研究进展  

Research progress of CAR-T cells targeting GPC3 in the treatment of liver cancer

作　　者：刘红静 谢正轶[1] 周旭延 段斯亮[1] Liu Hongjing;Xie Zhengyi;Zhou Xuyan;Duan Siliang(School of Basic Medical Sciences,Guangxi University of Science and Technology,Liuzhou 545006,China;School of Basic Medical Sciences,Guangxi Health Science College,Nanning 530023,China;Department of Gastrointestinal and Anus Surgery,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530023,China)

机构地区：[1]广西科技大学医学部,柳州545006 [2]广西卫生职业技术学院医学基础部,南宁530023 [3]广西中医药大学第一附属医院胃肠肛门外科,南宁530023

出　　处：《广西医科大学学报》2023年第9期1588-1596,共9页Journal of Guangxi Medical University

基　　金：国家自然科学基金青年科学基金资助项目(No.82003250);广西高校中青年教师科研基础能力提升项目资助(No.2020KY08029)。

摘　　要：嵌合抗原受体T细胞(CAR-T)是治疗肿瘤的新型免疫疗法,磷脂酰肌醇蛋白聚糖3(GPC3)在肝癌(HCC)组织中高表达,是治疗HCC的理想靶标,靶向GPC3的CAT-T细胞治疗HCC效果显著,被认为是最具潜力的免疫疗法之一。本文对靶向GPC3 CAR-T细胞治疗HCC的最新研究进展进行综述。The chimeric antigen receptor T cell(CAR-T)is a new type of immunotherapy method for treating tumors.Glypican-3(GPC3)is highly expressed in hepatocellular carcinoma(HCC)tissue,and has become an ideal target for treating HCC.CAT-T cells targeting GPC3 have significant positive effects on HCC,which is considered one of the most promising immunotherapy.This article reviews the latest research progress in CAR-T cells targeting GPC3 therapy for HCC.

关 键 词：嵌合抗原受体T细胞 肝癌 纳米抗体 磷脂酰肌醇蛋白聚糖3 实体肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]